

Case No. 4-30868A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV485023306US
Express Mail Label Number

June 7, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bernasconi et al.

Application No.: 09/955,381

Filed: September 18, 2002

For: NEW USE OF LIGANDS TO
GABA_B RECEPTORS

Examiner: Brannock, M. T.

Art Unit; 1646

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 19-0134. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Edward J. Wilusz, Jr.", with a stylized flourish at the end.

Edward J. Wilusz, Jr.
Reg. No. 52,370

Novartis

Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7960
June 7, 2005

60508624

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


Complete if Known

Application Number	09/955,381
Filing Date	September 18, 2001
First Named Inventor	Bernasconi
Art Unit	1646
Examiner Name	Brannock, M. T.
Case Number	4-30868A

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/955,381
Filing Date	September 18, 2001
First Named Inventor	Bernasconi
Art Unit	1646
Examiner Name	Brannock, M. T.
Case Number	4-30868A

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BRADFORD et al., "Neurotrophins in the Pathogenesis and Potential Treatment of Parkinson's Disease," <i>Parkinson's Disease: Advances in Neurology</i> , volume 80, chapter 3, pages 19-25, Gerald M. Stern, eds. (1999).	
	AB	SIEGEL et al., "Neurotrophic factors in Alzheimer's and Parkinson's disease brain," <i>Brain Research Reviews</i> , 33:199-227 (2000).	
	AC	ZEEVALK et al., "NMDA Receptors Modulate Dopamine Loss due to Energy Impairment in the Substantia Nigra but not Striatum," <i>Experimental Neurology</i> , 161:638-646 (2000).	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
60508624